Earn CME credit for this activity: https://www.naccme.com/program/2018-802-02 This on-demand webcast examines the efficacy and safety, indications, and cost utility of…
Browsing: Non-Small Cell Lung Cancer
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Edward B. Garon, M.D., MS Associate Clinical Professor, Director Of Thoracic Oncology Program, David Geffen School Of Medicine At UCLA,…
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides evidence for the use of stereotactic body radiation…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation…
Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend…
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for…
Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic…
Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for…
Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what…
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with…
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Drs. Langer, Aggarwal, Bazhenova, and…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses EGFR…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline…
Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Helen Ross discusses the…
Sanjay Popat, M.D., of The Royal Marsden Hospital Discusses ALTA-1L Trial CNS Efficacy. At ESMO Oncology Conference – Munich, Germany…
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states…
Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of…
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung…
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination…
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a…
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
GRACE – Global Resource for Advancing Cancer Education Published on Feb 25, 2016 Dr. Gerard Silvestri, Medical University of South…
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer…
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses precision medicine at the European Lung Cancer…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD,…
In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD,…
Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the…
Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small…
In this interview, Keith Kerr, MB, ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, UK, makes predictions on what…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Dean Fennell, PhD, FRCP, of the University of…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, talks about delivering personalized therapy for…
In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, discusses upcoming therapeutic targets for mesothelioma…
With the approval of new therapies that are restricted based on PD-L1 expression, there are many different assays to test…
Mamta Ruparel, MBBS, MRCP, of University College London, London, UK, discusses the current data and guidelines associated with the finding…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Giorgio Scagliotti, MD, PhD, from the University…
Speaking from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Federico Capuzzo, MD, PhD, of AUSL della Romagna,…
In this interview, Federico Capuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of…
Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Keith Kerr, MB, ChB, FRCPath, FRCPE, from…
In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of…
Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, discusses single target therapies in thoracic oncology and beyond…
Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest…